BFM
BDRX

Boothbay Fund Management’s Biodexa Pharmaceuticals BDRX Stock Holding History

Boothbay Fund Management’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-36
Closed -$120K – 1593
2023
Q4 		$120K Buy
+36
New +$153K ﹤0.01% 1412

Other funds holding BDRX

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boothbay Fund Management's BDRX Position: Q1 2024 in Review

Boothbay Fund Management sold out of Biodexa Pharmaceuticals (BDRX) in Q1 2024, closing a stake of 36 shares — an estimated $120K sold.

Boothbay Fund Management first reported a position in BDRX in Q4 2023 and held it in 1 quarter. The position peaked at $120K in Q4 2023. 3 funds tracked by Wall St. Rank hold BDRX as of Q1 2024.

  • Boothbay Fund Management reported no remaining Biodexa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 36 Biodexa Pharmaceuticals shares in Q1 2024, an estimated $120K.
  • Boothbay Fund Management first reported a position in Biodexa Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Boothbay Fund Management's Biodexa Pharmaceuticals position peaked at $120K in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.